Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by California Institute for Regenerative Medicine, Alimera Sciences, Durata Therapeutics and CoDa Therapeutics.
You may also be interested in...
Alimera To Resubmit Iluvien With No New Studies
FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.
Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.
Alimera To Resubmit Iluvien With No New Studies
FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.